U.S. markets open in 35 minutes
  • S&P Futures

    4,117.50
    -9.00 (-0.22%)
     
  • Dow Futures

    33,643.00
    -60.00 (-0.18%)
     
  • Nasdaq Futures

    13,739.75
    -54.50 (-0.40%)
     
  • Russell 2000 Futures

    2,180.90
    -3.10 (-0.14%)
     
  • Crude Oil

    61.24
    -1.43 (-2.28%)
     
  • Gold

    1,787.20
    +8.80 (+0.49%)
     
  • Silver

    26.18
    +0.34 (+1.34%)
     
  • EUR/USD

    1.2012
    -0.0029 (-0.24%)
     
  • 10-Yr Bond

    1.5660
    +0.0040 (+0.26%)
     
  • Vix

    18.88
    +1.59 (+9.20%)
     
  • GBP/USD

    1.3908
    -0.0029 (-0.21%)
     
  • USD/JPY

    108.0540
    -0.0160 (-0.01%)
     
  • BTC-USD

    55,452.89
    -805.68 (-1.43%)
     
  • CMC Crypto 200

    1,275.11
    +40.70 (+3.30%)
     
  • FTSE 100

    6,865.21
    +5.34 (+0.08%)
     
  • Nikkei 225

    28,508.55
    -591.83 (-2.03%)
     

SoftBank To Invest $900M In Pacific Biosciences - WSJ

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • SoftBank Group Corp (OTCMKTS: SFTBY) will reportedly invest $900 million into Pacific Biosciences of California Inc (NASDAQ: PACB), according to the Wall Street Journal, which comes on top of around 6% stake in PacBio that Softbank amassed almost a month back, worth over $350 million.

  • Last year, PACB was blocked by U.S. antitrust enforcers from merging with Illumina in a .2B deal. Illumina paid PacBio a $98 million breakup fee. But under their arrangement, if PacBio raised more than $100 million subsequently, it would owe Illumina $52 million. PacBio will now have to pay that amount.

  • The company recently announced a multi-year collaboration with Invitae Corp (NYSE: NVTA) to begin developing a production-scale high-throughput sequencing platform leveraging PacBio’s HiFi sequencing to expand Invitae’s whole genome testing capabilities.

  • Both companies committed resources to support the development.

  • Price Action: PACB gained 4.45% at $41.3 in premarket trading on the last check Wednesday, while NVTA closed 3.5% higher at $52.6 on Tuesday.

  • Image Courtesy: Wikimedia

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.